Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18909918 | MODIFIED DOUBLE-STRANDED RNA AGENTS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18885005 | Compositions and Methods Using CPG Oligonucleotides | September 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18814067 | MODIFIED DOUBLE-STRANDED RNA AGENTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18744370 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18428353 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | January 2024 | April 2025 | Allow | 15 | 0 | 1 | No | No |
| 18390233 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | December 2023 | June 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18534974 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18523558 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18515531 | MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18504548 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | November 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18491658 | Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18487338 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18463079 | PANCREATIC CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | September 2023 | August 2024 | Allow | 12 | 0 | 0 | No | No |
| 18449230 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | August 2023 | July 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18446743 | Methods for Treatment of Alport Syndrome | August 2023 | March 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18365787 | Novel Structurally Designed shRNAs | August 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18361772 | PLATELETS AS DELIVERY AGENTS | July 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18346099 | ANTISENSE OLIGOMERS TARGETING PCSK9 | June 2023 | May 2025 | Allow | 23 | 1 | 1 | No | No |
| 18340192 | Conjugated Antisense Compounds for Use in Therapy | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18204383 | STAUFEN1 AGENTS AND ASSOCIATED METHODS | May 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18320132 | SCARLESS GENOME EDITING THROUGH TWO-STEP HOMOLOGY DIRECTED REPAIR | May 2023 | July 2025 | Allow | 25 | 1 | 0 | No | No |
| 18319977 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | May 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18316693 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | May 2023 | November 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18302841 | COMPOSITIONS AND METHODS FOR TREATMENT OF SEPSIS-RELATED DISORDERS | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18299531 | Stabilized saRNA Compositions and Methods of Use | April 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18168004 | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION | February 2023 | March 2025 | Allow | 25 | 2 | 0 | No | No |
| 18167984 | METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18166204 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | February 2023 | October 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18159233 | 5-HALOURACIL-MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER | January 2023 | January 2025 | Allow | 24 | 2 | 0 | No | No |
| 18153428 | Oligonucleotides Comprising Modified Nucleosides | January 2023 | August 2024 | Allow | 20 | 1 | 1 | No | No |
| 18147156 | ARTIFICIAL GENOME MANIPULATION FOR GENE EXPRESSION REGULATION | December 2022 | August 2024 | Allow | 19 | 1 | 0 | No | No |
| 18145238 | Modified Double-Stranded RNA Agents | December 2022 | August 2024 | Allow | 19 | 1 | 1 | No | No |
| 18063511 | GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND ENGINEERED NANOPARTICLES TO PROVIDE TARGETED GENETIC THERAPIES | December 2022 | June 2025 | Allow | 30 | 1 | 1 | No | No |
| 18072202 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | November 2022 | March 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18058212 | Nucleoporins as Drug Targets for Anti-Proliferative Therapeutics | November 2022 | October 2024 | Allow | 23 | 1 | 1 | No | No |
| 17990402 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED MINICELLS AND METHODS OF USING THE SAME | November 2022 | May 2025 | Allow | 30 | 2 | 1 | No | No |
| 18046020 | CLICK-MODIFIED MRNA | October 2022 | November 2024 | Allow | 25 | 1 | 1 | No | No |
| 17963901 | GENE THERAPY FOR HAPLOINSUFFICIENCY | October 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 17933500 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | September 2022 | October 2024 | Allow | 25 | 1 | 1 | No | No |
| 17931493 | DOMINANT ACTIVE YAP, A HIPPO EFFECTOR, INDUCES CHROMATIN ACCESSIBILITY AND CARDIOMYOCYTE RENEWAL | September 2022 | July 2024 | Allow | 22 | 1 | 0 | No | No |
| 17942698 | RNAS FOR COMPLEMENT INHIBITION | September 2022 | July 2024 | Allow | 22 | 1 | 1 | No | No |
| 17941436 | MODIFIED DOUBLE-STRANDED RNA AGENTS | September 2022 | February 2025 | Allow | 29 | 1 | 1 | No | No |
| 17930345 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | September 2022 | June 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17930062 | RNA FOR TREATMENT OR PROPHYLAXIS OF A LIVER DISEASE | September 2022 | October 2024 | Abandon | 26 | 0 | 2 | No | No |
| 17900960 | Modified Guide RNAs | September 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17814407 | RAPID AND SPECIFIC EX-VIVO DIAGNOSIS OF CENTRAL NERVOUS SYSTEM LYMPHOMA | July 2022 | January 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17746360 | Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128 | May 2022 | March 2025 | Abandon | 34 | 3 | 1 | No | No |
| 17721704 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | April 2022 | October 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17694224 | METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST BCLXL AND MCL1 USING A POLYPEPTIDE NANOPARTICLE | March 2022 | June 2025 | Abandon | 39 | 2 | 1 | No | Yes |
| 17688276 | INHIBITION OF DNA POLYMERASES BY URACIL-DNA GLYCOSYLASE-CLEAVABLE OLIGONUCLEOTIDE LIGANDS | March 2022 | August 2024 | Allow | 30 | 1 | 0 | No | No |
| 17586175 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | January 2022 | July 2024 | Allow | 30 | 1 | 1 | No | No |
| 17574282 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE SECONDARY TO MULTIPLE SCLEROSIS | January 2022 | February 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17597533 | EXTRACELLULAR VESICLES CONTAINING MIR-142-3P TO TREAT FIBROSING DISEASES | January 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17597281 | OLIGOMERIC NUCLEIC ACID MOLECULE ACTIVATING ATOH1 GENE AND USE THEREOF | December 2021 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17534520 | 5-HALOURACIL-MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER | November 2021 | January 2025 | Allow | 38 | 4 | 0 | No | No |
| 17512270 | METHODS OF MODULATING RNA TRANSLATION | October 2021 | July 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17441596 | Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae | September 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17359902 | RNA ENCODING A THERAPEUTIC PROTEIN | June 2021 | July 2024 | Allow | 36 | 1 | 1 | No | No |
| 17343447 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | June 2021 | July 2024 | Allow | 37 | 2 | 1 | No | No |
| 17291449 | CODON-OPTIMIZED ABCB11 TRANSGENE FOR THE TREATMENT OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 2 (PFIC2) | May 2021 | April 2025 | Allow | 48 | 1 | 0 | Yes | No |
| 17234164 | LONG NON-CODING RNA GENE EXPRESSION SIGNATURES IN DISEASE MONITORING AND TREATMENT | April 2021 | December 2024 | Allow | 44 | 2 | 1 | No | No |
| 17191247 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | March 2021 | July 2024 | Allow | 40 | 1 | 1 | No | No |
| 17269714 | BIOMARKER FOR DIAGNOSING OR PREDICTING REACTIVITY OF OVARY TO FSH AND USE THEREOF | February 2021 | January 2025 | Allow | 47 | 2 | 0 | No | No |
| 17171288 | METHODS AND COMPOSITIONS RELATED TO RNA-TARGETED RHO SMALL GTPase RND3/RhoE THERAPY | February 2021 | June 2024 | Allow | 40 | 3 | 1 | No | No |
| 17171943 | BIOACTIVE RENAL CELLS | February 2021 | March 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17162226 | Antisense Compositions and Methods of Making and Using Same | January 2021 | January 2025 | Abandon | 48 | 3 | 1 | No | No |
| 17163015 | METHODS OF IN VIVO EVALUATION OF GENE FUNCTION | January 2021 | November 2024 | Allow | 46 | 1 | 1 | No | No |
| 17156002 | GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER | January 2021 | January 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17046514 | P16 POSITIVE TUMOR STRATIFICATION ASSAYS AND METHODS | October 2020 | October 2024 | Allow | 48 | 1 | 1 | No | No |
| 17065409 | THERAPEUTIC OLIGONUCLEOTIDES | October 2020 | October 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 17062422 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | October 2020 | October 2023 | Allow | 37 | 1 | 1 | No | No |
| 17043891 | MIR-17~92 AS THERAPEUTIC OR DIAGNOSTIC TARGET OF MOTOR NEURON (MN) DEGENERATION DISEASES | September 2020 | July 2024 | Allow | 45 | 1 | 1 | No | No |
| 16962552 | ADENO-ASSOCIATED VIRUS GENE THERAPY FOR 21-HYDROXYLASE DEFICIENCY | July 2020 | August 2024 | Allow | 49 | 1 | 1 | No | No |
| 16906619 | Deoxynucleic Guanidines (DNG)- Modified Oligonucleotides and Methods of Synthesizing Deoxynucleic Guanidine Strands | June 2020 | April 2025 | Allow | 58 | 4 | 1 | Yes | Yes |
| 16881919 | GENE KNOCKOUT OF NRF2 FOR TREATMENT OF CANCER | May 2020 | May 2024 | Allow | 48 | 4 | 1 | Yes | No |
| 16848679 | TREATMENT TARGETING ONCOLOGY AND NEURODEGENERATION | April 2020 | November 2024 | Allow | 55 | 2 | 1 | No | No |
| 16618251 | VIRAL VECTOR COMBINING GENE THERAPY AND GENOME EDITING APPROACHES FOR GENE THERAPY OF GENETIC DISORDERS | November 2019 | October 2024 | Allow | 59 | 4 | 2 | No | No |
| 16357765 | RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS | March 2019 | September 2019 | Allow | 6 | 0 | 0 | No | No |
| 16358013 | OLIGONUCLEOTIDE DECOYS FOR THE TREATMENT OF PAIN | March 2019 | January 2020 | Allow | 10 | 2 | 0 | No | No |
| 16299692 | MICRORNA-200 BASED APPROACHES FOR MODULATING BONE FORMATION INHIBITION AND BONE REGENERATION | March 2019 | March 2020 | Allow | 12 | 1 | 1 | No | No |
| 16071949 | PREDICTIVE METHODS OF ATHEROSCLEROSIS AND STENOSIS | July 2018 | October 2019 | Allow | 15 | 0 | 1 | No | No |
| 16039672 | METHOD FOR DIAGNOSING AND TREATING OVARIAN CANCER | July 2018 | September 2019 | Allow | 14 | 0 | 0 | No | No |
| 15779753 | DNA APTAMERS BINDING TO MOLECULAR TARGETED AGENTS AND DETECTION METHOD OF MOLECULAR TARGETED MEDICINE USING THE SAME | May 2018 | February 2020 | Allow | 20 | 1 | 0 | No | No |
| 15723966 | SPLICE-REGION ANTISENSE COMPOSITION AND METHOD | October 2017 | May 2019 | Allow | 19 | 1 | 0 | No | No |
| 15559362 | METHODS AND COMPOSITIONS INVOLVING TRANSMEMBRANE AND COILED-COIL DOMAINS 3 (TM-CO3) IN CANCER | September 2017 | October 2019 | Allow | 25 | 1 | 1 | No | No |
| 15643556 | METHODS AND MEANS FOR OBTAINING MODIFIED PHENOTYPES | July 2017 | September 2018 | Allow | 14 | 0 | 0 | No | No |
| 15525926 | COMBINATION LONG ACTING COMPOSITIONS AND METHODS FOR HEPATITIS C | May 2017 | January 2019 | Allow | 20 | 1 | 0 | No | No |
| 15583564 | MICRORNA-200 BASED APPROACHES FOR MODULATING BONE FORMATION INHIBITION AND BONE REGENERATION | May 2017 | December 2018 | Allow | 19 | 1 | 2 | No | No |
| 15515927 | ENHANCING DERMAL WOUND HEALING BY DOWNREGULATING MICRORNA-26A | March 2017 | November 2018 | Allow | 20 | 3 | 0 | No | No |
| 15504191 | OLIGONUCLEOTIDE DECOYS FOR THE TREATMENT OF PAIN | February 2017 | December 2018 | Allow | 22 | 1 | 1 | No | No |
| 15424758 | MEDICAL DEVICES | February 2017 | October 2018 | Allow | 20 | 1 | 1 | No | No |
| 15388681 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES | December 2016 | November 2019 | Allow | 35 | 2 | 1 | No | Yes |
| 15124916 | METHODS OF MODULATING WARS2 | September 2016 | August 2018 | Allow | 23 | 1 | 1 | No | No |
| 14885288 | RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE | October 2015 | June 2019 | Allow | 44 | 3 | 1 | No | No |
| 14870846 | RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS | September 2015 | December 2018 | Allow | 38 | 1 | 2 | No | No |
| 14740079 | ANTI-TUMOR COMPOSITIONS AND METHODS | June 2015 | October 2017 | Allow | 28 | 2 | 1 | No | Yes |
| 13633199 | NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION | October 2012 | April 2013 | Allow | 7 | 0 | 1 | No | No |
| 13568898 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | August 2012 | July 2013 | Allow | 11 | 0 | 1 | No | No |
| 13501267 | METHODS FOR DIAGNOSING AND TREATING A PATHOLOGY ASSOCIATED WITH A SYNONYMOUS MUTATION OCCURING WITHIN A GENE OF INTEREST | July 2012 | March 2014 | Allow | 23 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUDSON, AMY ROSE.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 44.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HUDSON, AMY ROSE works in Art Unit 1636 and has examined 266 patent applications in our dataset. With an allowance rate of 91.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner HUDSON, AMY ROSE's allowance rate of 91.4% places them in the 75% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HUDSON, AMY ROSE receive 1.55 office actions before reaching final disposition. This places the examiner in the 39% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUDSON, AMY ROSE is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +11.3% benefit to allowance rate for applications examined by HUDSON, AMY ROSE. This interview benefit is in the 50% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.2% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 53.8% of cases where such amendments are filed. This entry rate is in the 75% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 89.5% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.1% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 21.4% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.